Earnings Call · Q4 FY2025·2026-03-02

Q4 25EPS -9.94%·Rev n/aQ3 25EPS -1.47%·Rev n/aQ2 25EPS -28.05%·Rev n/aQ1 25EPS -16.46%·Rev n/a⚠ consensus missing

UroGen Pharma Ltd. URGN

Vincent I. Perrone — Chief Executive Officer

Elizabeth A. Barrett — Chief Executive Officer

Mark P. Schoenberg — Chief Medical Officer

David Lin — Chief Commercial Officer

Christopher Degnan — Chief Financial Officer

−12.4%1d on move date−12.4% vs SPY3d−7.1%5d−5.7%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more URGN calls or request research access.

More URGN calls Browse calls Request research access